Nuclear Medicine and Biology: Volume 80 to Volumes 91

Nuclear Medicine and Biology publishes original research addressing all aspects of radiopharmaceutical science: synthesis (automated and manual), in vitro and ex vivo studies, in vivo biodistribution by dissection or imaging, radiopharmacology, radiopharmacy, and translational clinical studies of new targeted radiotracers. The importance of the target to an unmet clinical need should be the first consideration.

These multidisciplinary studies should validate the mechanism of localization whether the tracer is based on binding to a receptor, enzyme, tumor antigen, or another well-defined target. The studies should be aimed at evaluating how the chemical and radiopharmaceutical properties affect pharmacokinetics, pharmacodynamics, or therapeutic efficacy. Ideally, the study would address the sensitivity of the tracer to changes in disease or treatment, although studies validating mechanism alone are acceptable as well.

If the synthesis of a new radiopharmaceutical is submitted without in vitro or in vivo data, then the uniqueness of the chemistry must be emphasized and should provide a substantial improvement over existing methodologies.

Radiopharmacy practice, addressing the issues of preparation, automation, quality control, dispensing, and regulations applicable to qualification and administration of radiopharmaceuticals to humans, is an important aspect of the developmental process, but only if the study has a significant impact on the field.

Contributions on the subject of therapeutic radiopharmaceuticals also are appropriate provided that the specificity of labeled compound localization and therapeutic effect have been addressed.

Volumes 80–81: Pages 1-70 (January–February 2020)

Volumes 82–83: Pages 1-96 (March–April 2020)

Volumes 84–85: Pages 1-110 (May–June 2020)

Volumes 86–87: Pages 1-66 (July–August 2020)

Volumes 88–89: Pages 1-96 (September–October 2020)

Volumes 90–91: Pages 1-104 (November–December 2020)